20260504_OMED_Laporan Informasi dan Fakta Material_32076897_lamp3.pdf

 1Q2026 Performance: OMED Records 31.1% Revenue Growth with
                    Improving Profitability
                                    Surabaya, May 4, 2026

PT Jayamas Medica Industri Tbk (IDX: OMED) recorded solid financial performance in the
first quarter of 2026, with strong revenue growth driven by higher sales volume across key
segments, alongside improving profitability.

The Company posted net sales of IDR 572.2 billion in 1Q2026, representing a 31.1% year-
on-year (YoY) increase compared to IDR 436.3 billion in the same period last year.

This growth was supported by a 54.1% YoY increase in sales volume to 941.9 million units.
The volume expansion was also in line with increased government healthcare spending at the
beginning of 2026, which contributed to stronger demand for medical devices in the domestic
market.

Amid strong volume growth, average selling prices (ASP) in several segments experienced
adjustments, particularly in high-volume products, as part of the Company’s strategy to expand
market penetration.

In line with revenue growth, the Company’s profitability improved across all levels. Gross profit
increased by 40.2% YoY to IDR 205.9 billion, with gross profit margin rising to 36.0% from
33.7% in the same period last year.

This was followed by strong operational performance, reflected in an increase in EBITDA
margin to 23.0%. The Company also recorded operating income of IDR 112.0 billion, up 67.8%
YoY, driven by operating leverage from higher sales volume.

Net profit reached IDR 99.0 billion, growing 35.4% YoY from IDR 73.1 billion in 1Q2025, with
net profit margin remaining solid at 17.3%, reflecting improving quality of earnings.

Operational Performance by Segment

The quarterly performance was supported by growth across most key segments:

   1. Medical disposable and consumables (BMHP) recorded strong volume growth of
      83.2% YoY, with total sales increasing by 22.6% YoY, despite ASP adjustments in line
      with the Company’s market penetration strategy.
   2. Wound care grew by 19.9% YoY, supported by increases in both volume and ASP.
   3. Antiseptic and dialysis fluid recorded stable growth of 12.6% YoY, driven by higher
      sales volume.
   4. Diagnostic and medical equipment posted significant growth of 68.6% YoY, supported
      by a surge in volume despite ASP adjustments.